Johnson & Johnson Reports Phase 3 GALAXI Results for Tremfya in Crohn's Disease

Johnson & Johnson today announced results from the Phase 3 GALAXI trials evaluating Tremfya (guselkumab) in patients with moderately to severely active Crohn's disease. The trials met their primary endpoints, demonstrating significantly higher rates of clinical remission and endoscopic response compared to placebo at week 12 and week 48. These results support regulatory submissions for Tremfya in Crohn's disease.